Podocyte Disorders: Core Curriculum 2011

J. Ashley Jefferson, MD FRCP\(^1\), Peter J. Nelson, MD\(^1\), Behzad Najafian, MD\(^2\), and Stuart J. Shankland, MD MBA\(^1\)

\(^1\)Division of Nephrology, University of Washington School of Medicine, Seattle, WA, United States

\(^2\)Department of Medicine, and Department of Pathology, University of Washington School of Medicine, Seattle, WA, United States

Introduction

There are approximately one million glomeruli in each human kidney. Each glomerulus is composed of a tuft of capillary loops supported by the mesangium and enclosed in a pouch-like extension of the renal tubule of the nephron known as Bowman’s capsule. The glomerulus consists of four resident cell types, the mesangial cell, the glomerular endothelial cell, the visceral epithelial cell (podocyte), and the parietal epithelial cell lining Bowman’s basement membrane. Recent experimental and clinical advances have identified the podocyte as the predominant cell of injury in glomerular diseases typified by heavy proteinuria, which is the focus of this article.

Structure, Function, and Injury of the Podocyte

Normal Structure of the Podocyte

- The podocyte is a highly differentiated epithelial cell sitting on the outside of the glomerular capillary loop
  - Consists of a large cell body (soma) in the urinary space
  - Connects to the underlying glomerular basement membrane (GBM) of the capillary loop by major cellular extensions from the soma
  - Extensions terminate as foot processes on the GBM that interdigitate with those from adjacent podocytes (Fig 1)
  - Podocyte foot processes are anchored to the GBM by \(\alpha_3\beta_1\) integrins and \(\alpha-\) and \(\beta\)-dystroglycans
  - Between the foot processes, the filtration slit is bridged by a 40-nm wide zipper-like slit diaphragm
    - Slit diaphragm highly permeable to water and small solutes
    - Small pore size (5–15 nm) of slit diaphragm limits the passage of larger proteins, including albumin
Nephrin is the major component of the slit diaphragm, and is linked to the actin cytoskeleton by CD2AP (CD2-associated protein), podocin, and others.

- Roughly 500–600 podocytes per glomerular tuft in the adult human kidney
  - Rate of turnover is very slow
  - Very limited ability to proliferate
- An extensive actin cytoskeleton
  - Allows dynamic contraction to support the glomerular capillary
  - Counteracts glomerular capillary hydrostatic pressure (~60 mm Hg), which is much greater than other capillary beds

**Major Functions of the Podocyte**

- Structural support of the capillary loop
- Major component of glomerular filtration barrier (GFB) to proteins
- Synthesis and repair of the GBM
- Production of growth factors
  - Vascular endothelial growth factor (VEGF) traverses the GBM against the flow of glomerular filtration
    - Acts on VEGF receptors on the glomerular endothelial cells
    - Effect is to maintain a healthy fenestrated endothelium
  - Platelet derived growth factors (PDGFs) critical for development and migration of mesangial cells into the mesangium
- Immunological function
  - Podocytes may be a component of the innate immune system
  - Possibly play a surveillance role for pathogens or abnormal proteins in Bowman’s space

**Glomerular Filtration Barrier**

**Glomerular Filtration of Plasma Water**

- Occurs across the glomerular capillary walls into the urinary (Bowman’s) space
  - Approximately 180 L/day filtered
  - A portion of the glomerular ultrafiltrate is not filtered directly into the urinary space
    - Instead, goes first to a space underneath the podocyte cell body (subpodocyte space)
    - Subpodocyte space may play a role in restricting hydraulic permeability
- GFB limits the passage of larger molecules such as albumin
  - Small amounts of protein (~4g/day) are normally filtered across the GFB into the urinary (Bowman’s) space
Vast majority of protein is reabsorbed in the proximal tubule via megalin/cubulin coreceptor

**Structure of GFB**
- Composed of three layers (Fig 1); damage to one or more layers leads to proteinuria
  - Layer closest to lumen: fenestrated endothelial cells coated with glycocalyx
    - Fenestrations facilitate hydraulic permeability
    - Overlying glycocalyx (composed of a network of proteoglycans with negatively charged glycosaminoglycan side chains) limits the passage of albumin and larger molecules
  - Middle layer: GBM
    - Major component is type IV collagen
      - Early \( \alpha_1 \alpha_2 \alpha_3 \) collagen network secreted by the glomerular endothelial cell during fetal development is replaced by the more robust \( \alpha_3 \alpha_4 \alpha_5 \) collagen network secreted by the podocyte
      - Failure to secrete this network results in a range of hereditary nephropathies, the Type IV collagenopathies
      - Type IV collagenopathies include Alport syndrome, nail patella syndrome, thin basement membrane disease, and can all be considered podocyte disorders
    - Other GBM components include the glycoproteins laminin, entactin, and nidogen, and heparan-sulfate proteoglycans
      - Laminin serves as the predominant cell attachment ligand for podocyte and endothelial integrins
      - Heparan-sulfate proteoglycans confer an overall anionic charge
  - Layer closest to urinary space: podocytes
    - Multiple examples of both inherited and acquired podocyte injury, especially to proteins comprising the slit diaphragm domain, demonstrate the critical role of the podocyte in the prevention of proteinuria
    - Podocytes also maintain the GFB by removing protein and immunoglobulins that may clog the filter
- Although injury to any layer may lead to proteinuria, nephrotic-range proteinuria is most typically due to diseases of podocytes

**Podocyte Responses to Injury in Disease**

**Overview**
- Glomerular diseases comprise a wide range of immune and non-immune insults that may target, and thus injure, the podocyte
- In many of these conditions, the podocytes respond to injury along defined pathways, which may explain the resultant clinical and histological changes
Reduction in Podocyte Number (Podocytopenia)

- Potential causes (can occur in combination)
  - Detachment: podocytes may lose their ability to anchor to the GBM, detach into Bowman’s space, and shed into the urine
  - Apoptosis: podocytes may undergo programmed cell death
  - Inability to proliferate
    ♦ Characteristic response of differentiated podocytes to most insults
    ♦ Podocytes lost by detachment or apoptosis are not replaced by adjacent viable podocytes, leading to podocytopenia
    ♦ Ultimate result is a leaky GFB

- Consequences of podocytopenia
  - Glomerular capillaries denuded of podocytes balloon and form synechial attachments to Bowman’s capsule
  - Kriz hypothesis: these attachments can lead to the development of focal segmental glomerulosclerosis (FSGS)
  - Recent evidence suggests that parietal epithelial cell precursors on Bowman’s basement membrane may serve as a source for podocyte replacement
  - Clinical studies in diabetic kidney disease have suggested that the degree of podocytopenia predicts progression of kidney disease

Podocyte Proliferation

- May be rarely seen in de-differentiated podocytes
- Feature of collapsing glomerulopathy

Foot Process effacement

- Characteristic feature of proteinuric diseases
  - Readily seen on electron microscopy as flattening of foot processes
  - The only pathological abnormality seen in minimal change disease (MCD)
- An active process induced by changes in the actin cytoskeleton
- The flattened foot processes, which should not be considered as cells adherent to one another, severely disrupt in the normal shape and integrity of these cells
- Other morphological changes characteristic of podocyte injury include microvillus transformation and the presence of protein reabsorption droplets
- It is unclear if effacement alone may cause proteinuria, or if effacement is simply a manifestation of podocyte injury

Altered Slit Diaphragm Integrity

- The slit diaphragm between adjacent podocyte foot processes is one of the major impediments to protein permeability across the glomerular capillary wall

*Am J Kidney Dis. Author manuscript; available in PMC 2012 October 1.*
• Alterations in cytoskeletal architecture and/or expression of slit diaphragm proteins can be demonstrated in most nephrotic disorders

**Production of Inflammatory Mediators**

• Podocytes may respond to immune complex-mediated injury by producing inflammatory mediators
  – Examples are oxidative radicals, proteases, eicosanoids, and chemokines, growth factors
  – Inflammatory mediators may amplify the initial podocyte injury
• Oxidative injury is a prominent feature in membranous nephropathy

**Suggested Reading**


**Nephrotic Syndrome**

**Classical Features of Nephrotic Syndrome**

• Heavy proteinuria (> 3.5 g/24 hr - also called nephrotic-range proteinuria)
• Hypoalbuminemia (< 3 g/dl)
• Peripheral edema
• Hyperlipidemia (elevated total and low-density lipoprotein cholesterol)
• Lipiduria

**Pathophysiology of Nephrotic Syndrome**

• Proteinuria and nephrotic syndrome are the clinical signatures of podocyte injury
  – Podocytes lie on the outside of the glomerular capillary, and are therefore separated from the circulation by the GBM
  – Subepithelial immune complexes (as in membranous nephropathy) or podocyte injury usually do not lead to leukocyte recruitment and inflammation, but rather disrupt the GFB
    ♦ Typically urine sediment is devoid of leucocytes and erythrocytes
    ♦ Disruption of GFB leads to proteinuria
• By contrast, injury to mesangial or endothelial cells, which are in direct contact with the blood (containing leucocytes, complement, inflammatory proteins),
typically leads to an inflammatory kidney disease (nephritis) with an active urine sediment

**Clinical Manifestations and Complications of Nephrotic Syndrome**

**Hypoalbuminemia and Edema**
- Hypoalbuminemia may decrease the plasma oncotic pressure resulting in a decrease in effective circulating volume and activation of the renin angiotensin system leading to sodium retention (underfill theory)
- In most cases however, edema appears to result from a primary defect in sodium excretion (ie, glomerular disease inhibits sodium excretion)
  - Leads to an expanded plasma volume
  - Followed by transudation of fluid in the setting of low oncotic pressure (overfill theory)

**Hyperlipidemia**
- Hepatic cholesterol and lipoprotein synthesis are increased in nephrotic patients, probably in response to decreased oncotic pressure
- There is also decreased catabolism, partly explaining the increase in levels of very low density lipoprotein

**Lipiduria**
- Following glomerular filtration of lipoproteins, lipids may be taken up by proximal epithelial tubular cells
- Desquamated proximal epithelial tubular cells containing lipid may be seen in the urine as oval fat bodies, or as lipid-containing granular casts (fatty casts)

**Thrombosis**
- Hypercoagulability from increased hepatic synthesis of coagulation factors (eg, fibrinogen) and loss of regulatory factors (antithrombin III, protein C and protein S) in the urine
- Kidney vein thrombosis complicates all forms of the nephrotic syndrome (especially membranous nephropathy)
  - May be asymptomatic
  - May present acutely as a sudden decrease in kidney function, loin pain, hematuria, or even systemic emboli

**Infection**
- Increased susceptibility to infection
  - Particular vulnerability to Gram-positive bacteria
  - Caused by urinary losses of IgG and complement, plus impaired cellular immunity

**Bone disease**
- Loss of vitamin D binding protein in the urine may lead to vitamin D deficiency
- Also, treatment with steroids may exacerbate bone loss
Common Causes of Nephrotic Syndrome

- Two categories of nephrotic syndrome etiology
  - Major pathology limited to, or predominantly, in the glomerulus
  - Systemic disorders, in which glomerular disease is a component of systemic manifestations (Box 1)
    - Systemic disorders do not manifest an idiopathic form limited to the glomerulus
    - Diabetic kidney disease is the most common systemic cause of nephrotic syndrome
    - Although mesangial cell injury is prominent in diabetic kidney disease, the proteinuria is likely a manifestation of podocyte injury
- Each of the glomerular disorders may be idiopathic, or associated with other secondary causes (eg, membranous nephropathy secondary to lupus)

General Therapeutic Strategies for Nephrotic Syndrome

- Reduce proteinuria (to < 1 g/24 hr)
  - Use combination therapy with angiotensin-converting enzyme inhibitors and diuretics [+/- angiotensin receptor blocker, spironolactone]
  - Proteinuria reduction may slow the progression of kidney disease by ameliorating the tubular toxicity of filtered proteins
- Treat any complications
  - Volume overload: salt restriction, diuretics
  - Hypertension: Blood pressure goal < 125/75 mm Hg.
  - Hyperlipidemia: statins
  - Thromboembolism: Aspirin; anticoagulation therapy for patients at high risk for venous thrombosis (eg, those with a serum albumin level < 2.0 g)
  - Bone disease: calcium and vitamin D supplementation
- Treat any underlying secondary cause (eg, Hepatitis B in membranous nephropathy)
- Provide disease-specific therapy (typically immunosuppression)

Suggested Reading

Clinical Podocyte Disorders

Minimal Change Disease

Epidemiology

- Most common cause of nephrotic syndrome in children
- Vast majority (90%) of cases occur in children less than 10 years of age
- Therefore, most young children with nephrotic syndrome are treated empirically with steroids without kidney biopsy
- Causes 10%-15% of adult nephrotic syndrome
Etiology and Pathogenesis

- Podocyte injury typified by diffuse foot process effacement on electron microscopy
- Evidence for a possible T-cell mediated cytokine leading to podocyte injury (Box 2)
  - Interleukin-13 (IL-13) is a recent candidate
    - Serum IL-13 levels are increased in patients with MCD
    - Rats overexpressing IL-13 develop minimal change type lesions
  - Angiopoietin-like 4 (ANGPTL4): overexpression in rat podocytes leads to a steroid-sensitive nephrotic syndrome
- Proteinuria likely secondary to loss of slit diaphragm integrity and podocyte effacement; some evidence for decrease in glomerular charge barrier

Pathology

- Light microscopy: unremarkable
- Immunofluorescence: unremarkable (rarely, C1q or IgM staining, which may herald a worse prognosis)
- Electron microscopy shows characteristic diffuse effacement of podocyte foot processes (Fig 2C)

Clinical Features

- Presents with acute-onset nephrotic syndrome (may be very heavy proteinuria (>10g/24h))
- Associated features in adults
  - Include hematuria (~30%); hypertension (~40%); thrombosis (5%)
  - Acute kidney injury (AKI) occurs in 10%-25% (mostly older, severe nephrotic syndrome)
- In children, hypertension less common, AKI may occur

Treatment

- For adults, prednisone 1mg/kg daily (or 2mg/kg alternate days)
  - High dose until 2 weeks after complete remission (minimum 8 weeks)
  - Then taper over 2–4 months
  - Relapse rate is approximately 50%
    - Steroid dependent/multiply relapsing: each flare responds to steroid
    - Prolonged remission may be achieved with 3 month course cyclophosphamide (60%-70%) or with prolonged course of mycophenolate
  - Steroid resistant form occurs in 25%
    - failure to enter remission after 16 weeks high dose steroid
may respond to cyclosporin or mycophenolate

Steroid resistance suggests the possibility of not having identified FSGS on the biopsy specimen, due to sampling phenomenon

- Children are typically more steroid sensitive, but high relapse rate (~70%) and 30%-40% will have multiple relapses

Focal Segmental Glomerulosclerosis

Overview

- FSGS describes a histological pattern rather than a specific disease
- Can be idiopathic or due to secondary causes from a variety of underlying disorders (Table 1)
- “Focal” defines that less than 50% of glomeruli in the sample are affected
- “Segmental” defines that only a portion of the effected glomerulus is sclerosed (scarred), while other portions of the glomerular tuft look normal by light microscopy

Epidemiology

- Increasing in prevalence
  - Has become the most common cause of nephrotic syndrome in adults
  - Higher prevalence in Black and Hispanic races
  - Most common cause of primary glomerular disease leading to end-stage renal disease (ESRD) in the US
- Although often considered a more advanced manifestation of MCD, many clinico-pathological features suggest FSGS is a completely separate group of diseases
- FSGS often responds poorly to steroid therapy and commonly progresses to kidney failure

Pathology

Light microscopy

- Lesion is defined by the early presence of an adhesion between a peripheral capillary loop and Bowman’s capsule
  - Progressive obliteration of the glomerular capillary lumen by acellular matrix-like material (Fig 2D)
  - Leads to a segmental scarring of the glomerular tuft
- Uninvolved areas of the glomerular tuft are relatively normal
- In addition to the clinical / etiological classification (Table 1), FSGS may be classified by histological features (Box 3)

Immunofluorescence

- C3, IgM, and fibrin staining in the sclerotic regions; otherwise unremarkable
Electron microscopy

- Diffuse effacement of podocyte foot processes even in glomeruli seemingly uninvolved on light microscopy

Pathogenesis

- Proteinuria due to an alteration in glomerular perm-selectivity in a similar manner to MCD (may be the glomeruli that appear normal on light microscopy that are mostly responsible for the proteinuria)
- Ultrastructural examination of the podocyte shows evidence of cell injury with foot process effacement, cell hypertrophy, and the formation of pseudocysts
- Podocyte detachment and apoptosis
  - Reduction in podocyte number
  - Loss of structural support to the capillary loop
  - Areas of denuded GBM, which can attach to the overlying parietal epithelial cells on Bowman’s basement membrane, forming synechiae
- Capillary loops within the adhesion may deliver filtrate into interstitial areas rather than Bowman’s space, but ultimately collapse with thrombosis and hyalinosis

Primary FSGS

- Immunological injury to the podocyte; exact mechanisms remain unclear
- Circulating Permeability Factor
  - The rapid recurrence of primary FSGS after kidney transplant, sometimes as early as the first week, suggests a circulating host factor leads to podocyte injury
  - Cardiotrophin-like cytokine 1 (CLC1) is a recently proposed candidate

Secondary FSGS

- Glomerular hyperfiltration: Loss of nephrons (reduced nephron mass) or dilation of the afferent arteriole (eg, obesity) may lead to glomerular hypertension and hyperfiltration
- Chronic glomerular hypertension promotes podocyte injury and distension of the glomerular capillary
- Glomerulomegaly (larger glomeruli may be more vulnerable to hyperfiltration injury and it is often the larger juxtamedullary glomeruli that develop glomerulosclerosis)
- Black individuals have fewer, and larger glomeruli than Caucasians, which may partly explain the greater prevalence of FSGS
- Nephron endowment
  - New nephrons continue to develop in the third trimester
  - Children born prematurely may have a decreased nephron number
  - Could predispose to glomerular hyperfiltration, with increased kidney disease and hypertension in later life
Clinical Features

Primary FSGS

- Typically presents with severe nephrotic syndrome, which may be of acute onset
- Associated with hematuria (~50%), hypertension (~60%) and reduced kidney function (25%-50%)
- Prognosis heavily dependent on achievement of partial/complete remission with immunosuppression
- Nonresponders have only 40% chance of a ten-year kidney survival

Secondary FSGS

- Typically slower onset, less proteinuria
- Serum albumin often preserved, less edema
- Does not respond to immunosuppression, but overall prognosis much better

Treatment

- Differentiate primary from secondary FSGS, as the latter are typically not steroid responsive
  - Clinical: assess for secondary causes, acuteness, and severity of nephrotic syndrome
  - Pathological: secondary FSGS suggested by glomerulomegaly, perihilar variant, and focal (<50%) effacement of foot processes
- General therapy for nephrotic syndrome
- Immunosuppression (for primary FSGS only) (Table 2)
  - Prednisone 1mg/kg (or 2mg/kg alternate days); prolonged course (up to 4 months) may be required before taper
  - Steroid resistant (50%): Consider cyclosporin 3–6mg/kg/day or mycophenolate mofetil 1g-1.5g bid

Special Considerations

Collapsing Glomerulopathy

- Classified as a pathological variant of FSGS, but many consider this a separate disease entity
- Most commonly described secondary to HIV, but other secondary causes noted (Box 4)
- Characteristic feature is the extracapillary proliferation of glomerular epithelial cells with collapse of glomerular tuft
- Recent evidence suggests that podocyte injury results in de-differentiation and a renewed ability to proliferate and/or induction of aberrant hyperplastic repair by the parietal epithelial cells
- HIV-associated nephropathy (HIVAN)
  - Almost exclusively in patients of African descent; associated with low CD4 counts and more advanced HIV infection
- Typically presents with severe nephrotic syndrome, often progresses rapidly to ESRD (< 12months)
- Surprisingly, patients are often normotensive
- Evidence for direct infection of podocytes by HIV; tubular cell infection may account for the prominent tubular microcystic changes often found
- Treatment with highly active antiretroviral therapy has dramatically changed the prevalence and prognosis for this condition

- Non-HIV collapsing glomerulopathy
  - Predominately in patients of African descent, but more whites noted than in HIVAN
  - Clinical features and pathology similar to HIVAN; tubuloreticular structures are not typically found in non-HIV collapsing glomerulopathy

**Familial FSGS**
- Present at different ages with different modes of inheritance (Table 3)
- Genetic testing is clinically available for most of these conditions
- Establishing diagnosis may alter therapy as these disorders are typically resistant to immunosuppression
- Familial FSGS is less likely to recur post-transplant
- Sequence variants in the *APOL1* (aloplipoprotein L-I) gene have been identified in African American patients with sporadic FSGS and hypertensive nephrosclerosis, which partly accounts for the increased prevalence in this group

**Recurrent FSGS Posttransplant**
- Primary FSGS recurs in 20%-30% of patients
  - Typically within the first month, but can occur later
  - Early recurrence supports theory of circulating permeability factor
- Graft loss 40%-50% without plasmapheresis
- Treatment: plasmapheresis for 2–3 weeks, longer in some; cyclophosphamide may be appropriate
- Risk Factors for recurrence
  - Young Age(< 15yrs)
  - Aggressive Course (< 3yrs from diagnosis to ESRD)
  - Race (less common in African Americans)
  - Living Donor (some recommend avoiding living donors in those at high risk for recurrence, but data not clear)

**Membranous Nephropathy**

**Epidemiology**
- Membranous nephropathy (MN) is most common cause of nephrotic syndrome in Caucasians and older adults
• Seen more often in males, rare in children
• Mostly primary (idiopathic), although about 20% of cases are associated with clinical conditions such as cancer, infections, autoimmune disease and drugs (Box 5)
• Familial membranous nephropathy has been described, but is rare

Etiology and Pathogenesis
• Characterized by the development of immune complexes in the subepithelial (subpodocyte) space
• In primary MN, immune deposits likely develop in situ, due to the passage of preformed antibodies across the capillary wall targeting a specific podocyte antigen
• The immune deposits consist of immunoglobulin (IgG, predominantly IgG4), complement components (C3, C5b-9), and antigen
  – Leads to podocyte damage, which causes increased production of extracellular matrix proteins along the GBM
  – Results in the characteristic thickening of the GBM, from which the name of the disease derives
• Antigens in MN
  – M-type phospholipase A2 receptor (PLA2R)
    ♦ Antibodies to PLA2R have been identified in 70% of patients with idiopathic MN
    ♦ Antibody levels may correlate with disease activity and help identify patients suitable for immunosuppression
    ♦ Anti-PLA2R antibodies not found in secondary forms of MN
  – Neutral endopeptidase: identified as the antigen in alloimmune neonatal MN occurring in newborns from neutral endopeptidase-deficient mothers
  – Subepithelial deposits of secondary MN
    ♦ Believed to derive from circulating pre-formed immune complexes that dissociate and reform in the subepithelial space, or by the deposition of antigen alone (planted antigen), followed by antibody response
    ♦ Range of antigens have been detected, including tumor antigens (carcinoembryonic antigen, prostate specific antigen), thyroglobulin, infection antigens (hepatitis B, hepatitis C, helicobacter pylori, syphilis) and DNA associated antigens (double-stranded DNA, histones, nucleosomes)
    ♦ Unclear if antigens are causal or epiphenomena
  – Heymann nephritis model
    ♦ A rat model of MN that has played a key role in identifying many of the pathogenic mechanisms in MN
    ♦ Pathogenic antigen is megalin, but this is not expressed by human podocytes
• Complement activation occurs, likely via the alternate pathway
  – C5b-9 is generated and inserts into podocyte membrane
  – Instead of cell lysis, a series of signaling events result in cell activation
    (release of reactive oxygen species, proteases and eicosanoids) and
    changes in podocyte structure

Pathology

Light Microscopy
• At early stages, the glomeruli and interstitium look essentially normal
• With disease progression, the pathognomonic thickening of capillary loops
  becomes evident
  – Accumulation of sub-epithelial immune complexes
  – Deposition of new basement membrane material by the podocyte
• Staining with silver methenamine may reveal spikes representing new basement
  membrane material projecting between the immune deposits (Fig 2I)
• Glomerular cellularity is typically normal

Immunofluorescence
• Granular deposits of IgG in a subepithelial distribution (Fig 2J)
• C1q, IgA, and IgM undetectable
• Complement C3 present in about 50% of adult patients

Electron Microscopy
• Characteristic subepithelial immune deposits
  – Initially small without a prominent basement membrane response
  – With time, basement membrane material projects around and encloses the
    immune deposits (Fig 2K)
• Effacement of podocyte foot processes is found overlying the areas of electron
  dense deposits
• Biopsy features suggestive of secondary MN include mesangial hypercellularity,
  leukocyte infiltration, the presence of C1q, IgA or IgM by immunofluorescence, or
  the presence of mesangial/subendothelial immune deposits or tubuloreticular
  structures by electron microscopy (Fig 2L)

Clinical Features of Idiopathic MN
• Typically presents as nephrotic syndrome (80%), onset more gradual than MCD or
  primary FSGS
• Associated features
  – Microhematuria is common (50%)
  – Blood pressure and kidney function typically normal at presentation.
• Less severe disease in younger females and Asian race
• Risk of kidney vein thrombosis higher than other forms of nephrotic syndrome
Natural History and Prognosis of Idiopathic MN

- Course in adults is variable, but about 30%-40% develop progressive disease
- 30% undergo spontaneous remission (especially in younger females)
- Prognostic risk factors for progression include:
  - Greater degree and duration of proteinuria
  - Impaired kidney function at presentation
  - Hypertension
  - Male sex and age older than 50 years
  - Non-Asian race
  - Biopsy features

  ♦ glomerulosclerosis, FSGS, Stage III/IV disease, tubulointerstitial fibrosis
  ♦ Has been argued that the pathological features on kidney biopsy do not give further prognostic risk stratification independent of the clinical variables

  - The urinary excretion of biomarkers such as $\beta_2$-microglobulin and/or IgG may be more accurate prognostic indicators than total urinary protein excretion, although these assays are not widely available

Treatment of Idiopathic MN

- Exclusion of Secondary Causes
  - Thorough history and examination
  - Check of antinuclear antibody, complement levels, Hepatitis B and C
  - Malignancy Screen

    ♦ In general, the risk of malignancy is greatest in males and increases with age
    ♦ Rare in those less than 40 years of age

  - Investigations may include stool guaics, colonoscopy, chest radiography, mammography and prostate specific antigen measurements
  - Screening recommendations are similar to the age appropriate cancer screening investigations for the general population

- Assessment of Prognosis
  - Treatment is individualized based on the prognostic risk factors
  - Almost all patients are treated with the general measures outlined in the section on treatment of nephrotic syndrome

- Immunosuppression is considered for patients at higher risk of progression (Table 4)

  - If the nephrotic syndrome is not too severe, 6 months’ close observation is often employed to determine if there is any evidence of a spontaneous remission (occurs in ~30% patients)
Cyclophosphamide or calcineurin inhibitor with steroid is usual first line therapy

- Steroids alone are typically ineffective

Emerging data on rituximab is promising

**Suggested Reading**


**Box 1: Common Causes of Nephrotic Syndrome**

**Predominant Glomerular Disease**

- Minimal Change Disease (see Box 2 for secondary causes)
- FSGS (see Table 3 for secondary causes)
- Collapsing Glomerulopathy (see Table 4 for secondary causes)
- Membranous Nephropathy (see Table 5 for secondary causes)
- MPGN

**Systemic Disorders with Glomerular Component**

- Diabetic kidney disease
- Amyloidosis

*Note:* Podocyte injury is prominent in each of these conditions. Note that nephritic glomerular disorders [eg, IgA nephropathy] may also present with nephrotic-range proteinuria. Rare causes of nephrotic syndrome include fibrillary glomerulopathy.
**Box 2: Secondary Causes of Minimal Change Disease**

**Tumors (often T cell related)**
- Hodgkin’s lymphoma
- Thymoma

**Drugs and toxins**
- NSAIDs
- Lithium
- Bisphosphonate
- Rarely: tiopronin, ampicillin, rifampicin, interferon

**Other**
- Atopy/eczema
- Chronic graft versus host disease

Abbreviations: NSAID, nonsteroidal anti-inflammatory drug

**Box 3: Columbia Pathological Classification of FSGS**

**Not otherwise specified (NOS)**
- Classic FSGS

**Perihilar variant**
- Exemplified in Figure 2E
- More common in FSGS second to hyperfiltration as glomerular pressure highest closer to afferent arteriole (ie perihilar)

**Tip variant**
- Exemplified in Figure 2F
- Tuft adhesion at glomerular tip (the area adjacent to the origin of the proximal tubule, opposite the vascular pole)
- Usually idiopathic, may be more steroid responsive

**Cellular variant**
- Exemplified in Figure 2G
- Segmental endocapillary hypercellularity
- Intermediate prognosis between NOS and collapsing

**Collapsing variant**
- Exemplified in Figure 2H
• Tuft collapse with proliferation of overlying epithelial cells
• Worst prognosis
• Many consider this a separate disorder (collapsing glomerulopathy)

Abbreviations: NOS, not otherwise specified; FSGS, Focal Segmental Glomerulosclerosis

Box 4: Causes of Collapsing Glomerulopathy

**Infection**
- HIV
- CMV
- Parvovirus B19
- Tuberculosis

**Malignancy**
- Myeloma
- Hemophagocytic syndrome
- Acute leukemia

**Drugs**
- Bisphosphonates
- Interferons
- Anabolic steroids

**Autoimmune**
- Adult Still’s disease
- Lupus
- Mixed connective tissue disease

Abbreviations: HIV, human immunodeficiency virus; CMV, cytomegalovirus

Box 5: Secondary Causes of Membranous Nephropathy

**Tumors**
Carcinoma (lung, colon, rectum, stomach, breast, kidney), melanoma, leukemia/lymphoma

**Infections**
Hepatitis B, hepatitis C, syphilis, quartan Malaria, schistosomiasis, filariasis, hydatid disease, leprosy, scabies, tuberculosis

**Drugs and Toxins**
Gold, penicillamine, bucillamine, captopril, probenecid, NSAIDs, tiopronin, lithium, mercury, formaldehyde, hydrocarbons

**Autoimmune Diseases**
Systemic lupus erythematos, rheumatoid arthritis, mixed connective tissue disease, Sjogren syndrome, Graves disease, Hashimoto thyroiditis, dermatomyositis, primary biliary cirrhosis, bullous pemphigoid, dermatitis herpetiformis, ankylosing spondylitis, Guillain-Barre syndrome, myasthenia gravis

**Miscellaneous**

Diabetes mellitus, sarcoidosis, sickle cell anemia, kimura disease, sclerosing cholangitis, systemic mastocytosis, Gardner-Diamond syndrome

Abbreviations: NSAID, nonsteroidal anti-inflammatory drug
Figure 1. Glomerular capillary wall
The 3 layers of the capillary wall (glomerular endothelial cell, glomerular basement membrane (GBM), and podocyte) act as the glomerular filtration barrier (GFB) preventing proteins and large molecules from passing from the capillary lumen into the urinary space. The podocyte cell body lies with the urinary space, and the cell is attached to the GBM via the foot processes. Adjacent foot processes are separated by the filtration slit, bridged by the slit diaphragm. Disruption of the GFB leads the passage of protein across the capillary wall leading to proteinuria.
Figure 2. Renal Pathology of Clinical Podocyte Disorders

(A) Light microscopy image of a normal glomerulus, Jones methenamine silver (JMS) stain; (B) Electron micrograph of a capillary loop from a normal glomerulus. Arrow heads point to regularly arranged intact foot processes. cap = capillary lumen, GBM = glomerular basement membrane, p = podocyte, e = endothelial cell; (C) Extensive effacement of foot processes (arrowheads) in minimal change disease. Spiral arrows point to microvillus transformation of podocytes; (D) Focal segmental glomerulosclerosis (FSGS), not otherwise specified (NOS) with obliterated capillary loops (*), hyalin deposition and adhesion of tuft to Bowman's capsule, periodic acid Schiff (PAS) stain; (E) FSGS, perihilar variant with segmental sclerosis at the vascular pole (*), PAS; (F) FSGS, tip variant with segmental...
sclerosis (arrow) located at the glomerulotubular junction (*), JMS; (G) FSGS, cellular variant with foam cells (arrowhead) infiltrating capillary loops of sclerotic segment and prominent overlying podocytes (spiral arrow), but no collapse of capillary loops, JMS; (H) FSGS, collapsing variant with collapse of capillary loops and podocyte proliferation (*), JMS; (I) Membranous nephropathy with thickened glomerular basement membrane. The inset shows a magnified view of capillary loops with frequent GBM holes (arrow) and spikes (arrowhead); (J) Immunofluorescent staining for IgG in membranous nephropathy shows global fine granular peripheral capillary wall staining pattern; (K) Electron micrograph of membranous nephropathy with subepithelial immune complex deposits (arrowhead) and extensive effacement of foot processes; (L) Electron micrograph of a case of membranous nephropathy secondary to lupus erythematosus. Arrow heads show subepithelial deposits and arrow shows an endothelial tubuloreticular inclusion, a common finding in lupus nephritis.
Table 1

Etiological Classification of FSGS

<table>
<thead>
<tr>
<th>Classification/Etiology</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td></td>
</tr>
<tr>
<td>? Circulating permeability factor</td>
<td>• Idiopathic</td>
</tr>
<tr>
<td>Secondary</td>
<td></td>
</tr>
<tr>
<td>Glomerular hyperfiltration</td>
<td>• Reduced nephron mass</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral infection</td>
<td>• HIV, parvovirus B19, CMV</td>
</tr>
<tr>
<td>Drugs &amp; toxins</td>
<td>• Heroin, pamidronate, lithium, anabolic steroids, interferon</td>
</tr>
<tr>
<td>Familial</td>
<td></td>
</tr>
<tr>
<td>Podocyte gene disorder</td>
<td>• Nephrin, podocin, INF2, α-actinin 4, CD2AP, WT1; TRPC6; phospholipase Cε1</td>
</tr>
</tbody>
</table>

Abbreviations: HIV, human immunodeficiency virus; CMV, cytomegalovirus; FSGS, Focal Segmental Glomerulosclerosis; INF2, inverted formin 2; CD2AP, CDs-associated protein; WT1, Wilms tumor 1; TRPC6, transient receptor potential cation channel 6;
### Table 2
Immunosuppressive Treatment for Adult MCD and primary FSGS

<table>
<thead>
<tr>
<th></th>
<th>Initial Approach</th>
<th>Prednisone Duration</th>
<th>Second-line Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Minimal Change Disease</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial Therapy</td>
<td>Prednisone (1 mg/kg) (max of 80 mg/d)</td>
<td>Until 2 wk post complete remission (min of 8 wk) Taper over 2–4 mo</td>
<td>NA</td>
</tr>
<tr>
<td>Steroid Resistant</td>
<td>Prolonged high-dose steroid course</td>
<td>Discontinue after 4–6 mo if no response</td>
<td>MMF; cyclosporine; tacrolimus</td>
</tr>
<tr>
<td>Relapsing / steroid dependent</td>
<td>Try to detect early Repeat prednisone (1 mg/kg) Consider MMF or cyclosporin for induction</td>
<td>Shorter steroid course (4 wk high dose, taper 1–2 mo), then second-line agent</td>
<td>Oral cyclophosphamide (2 mg/kg for 12 wk); MMF; calcineurin inhibitors; rituximab</td>
</tr>
</tbody>
</table>

| **Focal Segmental Glomerulosclerosis** |                                               |                                               |                                           |
| Initial Therapy     | Prednisone (1 mg/kg) (max 80 mg/d)            | Until 2 wk post complete remission (min 8 wk), then taper 2–4 mo | n/a                                       |
| Partial Remission   | Prolonged steroid course, as late complete remissions seen | High-dose steroid for 3–4 mo, then slow taper over 6–9 mo | Calcineurin inhibitors; MMF               |
| Steroid Resistant   | Prolonged steroid course                       | High dose for 4 mo Add second-line agent with taper | Calcineurin inhibitors; MMF               |
| Relapsing / steroid dependent | Treat as MCD (above)                          | NA                                            | NA                                        |

Abbreviations: FSGS, focal segmental glomerulosclerosis; MMF, mycophenolate mofetil; MCD, Minimal Change Disease; max, maximum; min, minimum; NA, not applicable
Table 3

Common Forms of Familial FSGS

<table>
<thead>
<tr>
<th>Gene (protein affected)</th>
<th>Inheritance</th>
<th>Typical Age of Onset</th>
<th>Distinguishing Clinical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPHS1 (nephrin)</td>
<td>AR</td>
<td>infancy</td>
<td>Congenital nephrotic syndrome (Finnish type); severe nephrosis leading to ESRD</td>
</tr>
<tr>
<td>NPHS2 (podocin)</td>
<td>AR</td>
<td>3 mo-5 y</td>
<td>10–20% of SRNS in children</td>
</tr>
<tr>
<td>WT1 (Wilms tumor 1)</td>
<td>AD</td>
<td>child</td>
<td>Diffuse mesangial sclerosis/FSGS +/- Wilms tumor or urogenital lesions</td>
</tr>
<tr>
<td>PLCε1 (phospholipase Cε1)</td>
<td>AR</td>
<td>&lt;6 y</td>
<td>Diffuse mesangial sclerosis/FSGS</td>
</tr>
<tr>
<td>CD2AP (CD2- associated protein)</td>
<td>AR</td>
<td>&lt;6 y</td>
<td>Rre, progresses to ESRD</td>
</tr>
<tr>
<td>INF2 (inverted formin 2)</td>
<td>AD</td>
<td>Teen/young adult</td>
<td>Mild nephrotic syndrome, but progressive CKD</td>
</tr>
<tr>
<td>ACTN4 (α- actinin 4)</td>
<td>AD</td>
<td>Any age</td>
<td>Mild nephrotic syndrome, may develop progressive CKD</td>
</tr>
<tr>
<td>TRPC6</td>
<td>AD</td>
<td>Adult (age 20-35)</td>
<td>Nephrotic, progressive CKD</td>
</tr>
<tr>
<td>tRNA&lt;sub&gt;Leu(UUR)&lt;/sub&gt; gene</td>
<td>Mitochondrial DNA</td>
<td>Adult</td>
<td>May be associated deafness, diabetes, muscle problems, retinopathy (maternal inheritance)</td>
</tr>
</tbody>
</table>

Abbreviations: AR, autosomal recessive; AD, autosomal dominant; CKD, Chronic Kidney Disease; ESRD, End-Stage Renal Disease; FSGS, Focal Segmental Glomerulosclerosis; tRNA, transfer RNA; Leu, leucine; TRPC6, transient receptor potential cation channel 6;
Table 4

Treatment of Membranous Nephropathy

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Approach</th>
<th>Immunosuppression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Risk (proteinuria &lt;4 g/d, normal kidney function)</td>
<td>General measures *</td>
<td>None</td>
</tr>
<tr>
<td>Moderate risk (proteinuria 4-8 g/d, normal kidney function)</td>
<td>General measures; observe for 6 mo</td>
<td>Cyclophosphamide + steroid (alternative is cyclosporin / tacrolimus)</td>
</tr>
<tr>
<td>High risk (proteinuria &gt;8 g/d +/- reduced kidney function)</td>
<td>General measures; consider early immunosuppression</td>
<td>Cyclophosphamide + steroid (alternative is cyclosporin / tacrolimus)</td>
</tr>
</tbody>
</table>

* see general measures for treatment of nephrotic syndrome.